Health
Bharat Biotechs Covaxin succeeds in challenge trials on Rhesus monkeys – Business Standard
The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey
Hyderabad-based Bharat Biotech has released the data from the animal trials of its vaccine candidate, which showed that Covaxin was able to generate ‘robust immune responses’.
The firm said that the vaccine prevented infection and disease in the primates upon high amounts of exposure to live virus Sars-CoV-2. This is called a challenge trial where a participant is exposed deliberately to the pathogen after being given the vaccine shot.
The company tweeted “Bharat Biotech proudly announces th…
-
Noosa News19 hours agoYoung voices shape Sunshine Coast’s future
-
Business19 hours ago2 Low Cost Active ASX ETFs to consider
-
General23 hours agoDonald Trump threatens China with additional 50 per cent tariff as trade war threatens to escalate
-
Noosa News17 hours agoStar Entertainment signs $300m lifeline deal with US gaming giant Bally’s